(Elbasvir + grazoprevir) is a Small Molecule owned by Merck & Co, and is involved in 51 clinical trials, of which 45 were completed, and 6 are ongoing.
Elbasvir is an inhibitor of HCV NS5A. NS5A is a multifunctional phosphoprotein and an essential component of the viral RNA replication machinery. HCV NS5A antagonizes numerous cellular pathways, including the antiviral interferon-a response. NS5A has the capacity to bind to the 3-ends of HCV plus and minus strand RNAs. The mechanism of action of elbasvir has been characterized based on cell culture antiviral activity and drug resistance mapping studies.
Grazoprevir is an inhibitor of the HCV NS3/4A protease. The NS3 protein is a multi-functional protein, with a serine protease domain in its N-terminal one-third and a helicase domain in the C-terminal two-third, which is necessary for the proteolytic cleavage of the HCV encoded polyprotein (into mature forms of the NS3, NS4A, NS4B, NS5A, and NS5B proteins) and is essential for viral replication.
The revenue for (Elbasvir + grazoprevir) is expected to reach a total of $244m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Elbasvir + grazoprevir) NPV Report.
(Elbasvir + grazoprevir) is currently owned by Merck & Co.
(Elbasvir + grazoprevir) Overview
Grazoprevir (MK-5172) and Elbasvir (MK-8742) (Zepatier) is a fixed dose combination drug acts as an antiviral agent. It is formulated as film coated tablets and tablets for oral route of administration. Zepatier is indicated for the treatment of chronic hepatitis C (CHC) genotypes 1, 3, or 4 infection in adults as follows : Without ribavirin: in genotype (GT) 1 or 4 treatment-naïve (TN) and peginterferon alfa + ribavirin (PR) treatment-experienced (TE) relapsers (12 weeks), in GT1 protease inhibitor (PI)/PR-TE relapsers (12 weeks), in GT1b TN, non-cirrhotic patients (8 weeks), in GT1b PR- or PI/PR-TE on-treatment virologic failures (12 weeks), With Ribavirin : in GT1a PR- or PI/PR-TE on-treatment virologic failures (16 weeks), in GT4 PR-TE on-treatment virologic failures (16 weeks), With sofosbuvir: in GT3 TN patients (12 weeks). Zepatier is indicated for use with ribavirin in certain patient populations.
It is under development for the treatment of chronic hepatitis C (CHC) in paediatric patients 12 years of age and older who weigh at least 30 kg.
Merck & Co Overview
Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
The company reported revenues of (US Dollars) US$48,704 million for the fiscal year ended December 2021 (FY2021), an increase of 17.3% over FY2020. In FY2021, the company’s operating margin was 25.7%, compared to an operating margin of 12% in FY2020. In FY2021, the company recorded a net margin of 26.8%, compared to a net margin of 17% in FY2020. The company reported revenues of US$14,959 million for the third quarter ended September 2022, an increase of 2.5% over the previous quarter.
Quick View – (Elbasvir + grazoprevir)
|Highest Development Stage|